Human Immunodeficiency Virus (HIV1) Infection Market Size - Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

The human immunodeficiency virus (HIV1) infection market was valued at USD 20.64 Billion in 2025. It is poised to grow at a CAGR of 5.20% during the forecast period of 2026-2035, and reach USD 34.27 Billion by 2035. The market growth is driven by the rising global prevalence of human immunodeficiency virus infection, increasing awareness programs, expanded antiretroviral therapy access, and continuous advancements in long-acting and combination treatment options.

Q1 2026 Market Updates

Geopolitical Impact of Iran, US, and Israel War on the Human Immunodeficiency Virus (HIV1) Infection Market

United States: The Human Immunodeficiency Virus (HIV1) Infection Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. 31 force majeure declarations by polymer suppliers, polypropylene and polyethylene price spikes, and chemical manufacturer surcharges of up to 30% are flowing through supply chains. U.S. consumer inflation is projected at 4.2% for 2026, above pre-war forecasts, with fuel costs above USD 4 per gallon compressing household discretionary budgets. Retail supply chains are absorbing the combined impact of 30% higher freight costs, 15-20% packaging material inflation, and rising transport fuel costs, compressing retailer margins. Consumer spending caution is growing as gasoline above USD 4 per gallon and 4.2% projected inflation compress household discretionary budgets.

Iran: Iran's domestic Human Immunodeficiency Virus (HIV1) Infection sector has been effectively suspended by the conflict. US-Israeli strikes on industrial and civilian infrastructure across Tehran, Mashhad, Isfahan, and other major cities have disrupted all commercial activity. Power outages from attacks on electricity generation facilities have halted manufacturing operations, and the collapse of the commercial banking and logistics system has eliminated any residual trade flows. The broader humanitarian crisis, with over 1,900 casualties and 4,000+ civilian buildings damaged, has redirected the entire Iranian economy toward survival rather than production or consumption.

Israel: Israel's Human Immunodeficiency Virus (HIV1) Infection sector is experiencing near-term disruption from wartime conditions. Consumer spending on non-essential categories has declined as millions of Israelis regularly shelter from missile and drone alerts. Supply chain logistics are disrupted by regional airspace closures, elevated war-risk insurance premiums, and the suspension of major carrier services through the region. International business partnerships with Israeli companies have been temporarily suspended. Post-conflict reconstruction and recovery demand is expected to provide meaningful demand acceleration across affected market segments once operational conditions normalise.

Key Takeaways

Government

• Relevant consumer protection agencies should monitor retail pricing for evidence of disproportionate margin-taking on top of genuine supply cost increases, ensuring that conflict-related cost inflation is not being amplified by opportunistic pricing behavior.
• Governments should consider targeted consumer support measures for lower-income households most exposed to rising fuel and food costs, preventing conflict-driven inflation from creating acute hardship among economically vulnerable populations.
• Trade authorities should work with the human immunodeficiency virus (hiv1) infection industry to identify import diversification opportunities that reduce dependence on Gulf-disrupted supply chains, stabilizing product availability and moderating consumer price inflation.

Market

• U.S. consumer inflation projected at 4.2% for 2026, gasoline above USD 4 per gallon, and global food price increases from fertilizer and logistics inflation are creating the most challenging consumer spending environment since 2022.
• Premium and essential categories within the human immunodeficiency virus (hiv1) infection market show different demand trajectories: premium segments serving ultra-high-net-worth consumers remain resilient, while mass-market discretionary segments face meaningful softening.
• Supply chain cost increases from 30% higher freight, 15-20% packaging inflation, and rising input material costs are compressing retailer and brand margins, creating pressure for pricing adjustments that may further moderate volume demand.

Procurement

• Consumer goods procurement teams should review packaging material sourcing, building 60-90 day buffer inventory of petroleum-derived packaging materials before further feedstock cost increases from the Gulf supply shock are transmitted into manufacturing costs.
• Logistics procurement managers should lock in freight contracts at current rates before further diesel cost increases are passed through by carriers, and evaluate route optimization strategies that reduce fuel cost exposure.
• Retail and brand buyers should update 2026 cost models to incorporate 30% higher freight costs, 15-20% packaging material inflation, and rising input material prices, ensuring that margin targets and pricing strategies reflect the new cost environment.

Key Market Trends and Insights

• By drug class, integrase strand transfer inhibitors are expected to dominate the drug class segment, accounting for approximately 38% of the market, driven by superior efficacy, safety profile, and widespread adoption in first-line HIV treatment regimens globally.
• By distribution channel, hospital pharmacies are projected to hold the largest share at around 52%, supported by centralized treatment distribution, higher patient footfall, and strong institutional access to antiretroviral therapies.
• Based on region, the United States is anticipated to lead the market with nearly 41% share, attributed to high treatment coverage, advanced healthcare infrastructure, and strong presence of key pharmaceutical players.

Market Size and Forecast

• Market Size (2025): USD 20.64 Billion
• Projected Market Size (2035): USD 34.27 Billion
• CAGR (2026-2035): 5.20%